# A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Source: https://onco.cc/trials/nct07023627/  
OnCo record `nct07023627` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of INCB123667 in ovarian cancer, run by Incyte Corporation, now recruiting.

## Summary

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression is a phase 2 interventional study registered as NCT07023627 by Incyte Corporation, with 160 participants planned, started 2025-11-12 and due to reach its primary completion in 2027-04-27. Interventions recorded: INCB123667. Conditions listed: Ovarian Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07023627
- Phase: 2
- Setting: A Phase 2, Single-Arm Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression (MAESTRA 1)
- Sponsor: Incyte Corporation
- Enrolled: 160

## Sources

- ClinicalTrials.gov NCT07023627: https://clinicaltrials.gov/study/NCT07023627

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [INCB123667](https://onco.cc/drugs/incb123667/)
- companies: [Incyte](https://onco.cc/companies/incyte/)

---
JSON: https://onco.cc/api/v1/entities/nct07023627.json